◀ Back to EPO

EPO — PAFAH1B1

Text-mined interactions from Literome

Marsh et al., Semin Hematol 2007 (Anemia, Aplastic...) : In several uncontrolled and controlled studies, especially in low-risk MDS , high-dose erythropoietin (EPO) or its glycosylated derivative darbepoetin ( DPO ), alone or in combination with G-CSF, increased hemoglobin levels and diminished the need for red blood cell transfusions, in selected patients with prior transfusion frequency of less than 2 units per month and EPO levels below 500 IU/L. Quality-of-life measures were claimed to have improved, but the cost-effectiveness of this approach is debated, as is safety with regard to the risk of progression
Wu et al., Am J Hematol 1994 (Acute Disease...) : Using clonogenic assay we investigated the effect of stem cell factor (SCF) on the in vitro growth of clonogenic precursor cells from acute myeloid leukemia ( AML ) and myelodysplastic syndromes (MDS) in the presence or absence of recombinant human erythropoietin ( rhEpo ) or recombinant human granulocyte colony stimulating factor ( rhG-CSF )
Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes et al., Br J Haematol 1998 (Myelodysplastic Syndromes) : To evaluate the effect of recombinant human erythropoietin ( rHuEpo ) on the haemoglobin level and transfusion requirement in low-risk myelodysplastic syndromes (MDS) , 87 patients were enrolled in a randomized double-blind placebo controlled study, 44 patients were assigned to epoetin alpha ( 150 U/kg/d s.c. for 8 weeks ) and 43 to placebo arms